Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,204 INR | -1.47% | +3.13% | +7.01% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an enterprise value anticipated at 3.46 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.01% | 12.38B | - | ||
+32.82% | 704B | C+ | ||
+28.59% | 577B | B | ||
-3.79% | 348B | C+ | ||
+18.18% | 327B | B- | ||
+5.35% | 288B | C+ | ||
+14.81% | 234B | B+ | ||
+4.93% | 198B | B- | ||
-9.78% | 194B | A+ | ||
-3.91% | 147B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DRREDDY Stock
- DRREDDY Stock
- Ratings Dr. Reddy's Laboratories Limited